basophils. We focused on relationship of specific basophil reactivity in relationship to proportion of regulatory T cells. Methods: Forty-five patients with history of systemic symptoms of allergy to Hymenoptera venom were included. Basophil reactivity before the treatment and after one year of allergen immunotherapy (AIT) was measured by CD63 expression, CD203c marker used for basophil identification. Cells were stimulated by aqueous solution of allergen in concentration range 0.01 to 1 mg/mL. T regulatory cells were identified as CD4 positive, CD25 bright and CD127 negative at the same interval of treatment. Monoclonal antibodies conjugated with fluorochromes were used, measured by FACSCalibur. Paired t test and correlation analysis used for statistical evaluation. Results: Median Treg proportion before therapy was 2.160, after IT 1.960, basophil specific response (proportion of CD63 positive cells) at the same interval were 3.65 and 4.11 at 0.01 mg/mL, 13.1 and 16.1 for 0.1 mg/mL and 33.85 and 40.8 for 1 mg/mL. All differences were not statistically significant. Differences of basophil activation were not significantly related to proportion of T regulatory cells. Conclusions: In our group of patients with HV allergy, treated by AIT, we did not found any relationship between basophil specific activation during allergen immunotherapy and proportion of T regulatory cells.
Background: Up to 3% of the general population suffers from potentially lifethreatening systemic reactions after honeybee and wasp stings. Unfortunately, there are still individuals who have a convincing history of an anaphylactic event, but lack the necessary diagnostic, making difficult the decision for immunotherapy. Our aims were to evaluate the feasibility of using recombinant allergens in the Basophil activation test (BAT) for the diagnosis of Hymenoptera allergy and to develop a high-throughput diagnostic device combining the advantages of basophil activation tests with a panel of recombinant allergens: rVes v 1, rVes v 2, rVes v 3, rVes v 5, rApi m 1, rApi m 2, rApi m 3 and rApi m 5. Methods: Basophil activation test (BAT) and measurement of specific IgE was performed on 47 wasp venom, 14 Honeybee venom allergic patients and 17 healthy controls. Specificity and sensitivity of BAT performed with recombinant His-tag purified wasp venom allergens Ves v 1, Ves v 2, Ves v 3 and Ves v 5, recombinant honeybee venom allergens Api m 1, Api m 2, Api m 3 and Api m 5 and commercial extracts have been compared. Each patient had a history of grade I or II anaphylaxis after an insect sting. All patient sera were collected before initiation of SIT. Results: BAT performed with the panel of recombinant allergens markedly increased the specificity and the sensitivity in the detection of wasp venom allergic subjects. Background: The standard venom immunotherapy involves the administration of the maintenance dose every 4 to 6 weeks. This regimen may have compliance problem especially in the long term, thus extended intervals have been proposed. We prospectively compared the efficacy of 3-or 4-month extended maintenance dose and the conventional regimen. Methods: Patients receiving immunotherapy of a single venom were offered the delayed maintenance dose, and were then followed-up for field re-stings.
Only the re-stings by the insect for which the patients received immunotherapy were considered. A matched group of patients receiving the conventional maintenance were used for comparison, by univariate and multivariate analysis. Results: Fifty-two patients (44 male, 8 female, mean age 52 years) were certainly re-stung on 113 occasions by the insect for which they were receiving immunotherapy. 90 re-stings occurred during the 3-month maintenance and 23 during the 4-month maintenance. The control group, on conventional protocol with one single venom, included 103 patients (79 male, 24 female, mean age 41 years) certainly re-stung on 160 occasions by the specific insect. The rate of re-sting without reaction was 97% in the delayed maintenance and 82% in the conventional group with a significant difference in favour of the former (P ¼ 0.01). None of the variables considered resulted predictive for systemic reactions by logistic regression analysis Conclusions: The delayed maintenance dose approach is al least as effective and safe as the conventional one. The 4-month maintenance seems to be the best option in term of convenience and economic save.
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Serum CTLA-4 AND IL-10 in Hymenoptera Venom Immunotherapy: Equivalence of Different Induction Regimens Background: Cytotoxic T lymphocyte associated gene-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be downregulated by immunotherapy. We assessed the effects on CTLA4 of venom immunotherapy given by different induction protocols (classic, rush or ultra rush). Methods: Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. In the classical regimen, the induction lasted 6 weeks, in the rush protocol it lasted 3 days, and in the ultra-rush maintenance was achieved in 24 hours. Soluble IL-10 was assayed in the same samples for comparison. CTLA-4 and IL10 were measured by commercial immuoassays. Results: Seventy-six patients (52 male, mean age 35 years) were studied. Of them, 30 underwent the classic induction, 22 the rush and 24 the ultra rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction in all groups, thus irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, the same behaviour was observed with IL-10 that significantly increased at the end of the induction.
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